Christian Cortis

Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA.

ATV Capital Management Inc. (ATV Capital Management) is a venture capital firm founded in 1979. The firm is headquartered in Boston, Massachusetts.

Booz Allen Hamilton, Inc. engages in the provision of management and technology consulting services. Its services include consulting, analytics, digital solutions, engineering, cyber security, and product. The company was founded by Edwin G. Booz in 1914 and is headquartered in McLean, VA.

Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA.

OpenEye Scientific Software, Inc. engages in the development of large-scale molecular modeling applications and toolkits. Its solutions include lead discovery, toolkit development platform, custom code, jupyter notebooks, data preparation and crystallography. The company was founded by Anthony Nicholls in 1997 and is headquartered in Santa Fe, NM.

Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020.

PRCL Research Inc. is a special purpose company created to develop one compound to proof-of-concept. It engages in the development of a clinical candidate against a novel target for the treatment of chronic inflammatory diseases. The company was founded on October 4, 2013 and is headquartered in Montreal, Canada.